52

Jenburkt Pharmaceuticals LtdBOM 524731 Stock Report

Last reporting period 31 Mar, 2024

Updated 28 Oct, 2024

Last price

Market cap $B

0.023

Micro

Exchange

XBOM - Bombay Stock Exchange

524731.BO Stock Analysis

52

Avoid

Based on Eyestock quantitative analysis, 524731.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

90/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-33.7 %

Greatly overvalued

Market cap $B

0.023

Dividend yield

1.74 %

Shares outstanding

4.41 B

Jenburkt Pharmaceuticals Ltd. engages in the manufacture and marketing of pharmaceutical formulations and healthcare products. The company is headquartered in Mumbai, Maharashtra and currently employs 724 full-time employees. The firm offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The firm's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The firm's manufacturing plant is located in Sihor-Gujarat. The firm's products are exported to approximately 13 countries globally.

View Section: Eyestock Rating